Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Effects of GLP-1 Receptor Agonists in Heart Failure Patients
Author(s): Anastasia Shchendrygina , Amina Rakisheva , Ilya Giverts , et al Added: 9 months ago

Heart Failure
HFSA 24: STEP-HFpEF: Exercise Function and Frailty Status
Author(s): Mikhail Kosiborod Added: 8 months ago
HFSA 24 - We are joined virtually by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss findings from the STEP-HFpEF trial programme in regard to the efficacy of semaglutide according to frailty status, and exercise function at baseline.Interview Questions:1. Could you remind us of the importance of STEP-HFpEF2. What was the study design and patient population?3. What… View more

Heart Failure

Prevention & Chronic Conditions
ACC 24 Late-Breaker Discussion: The ARISE-HF Trial
Author(s): Harriette Van Spall , James L Januzzi Added: 1 year ago
ACC 2024 — Late-breaker host Dr Harriette Van Spall (McMaster University, CA) sits down with Dr James L. Januzzi (Massachusetts General Hospital & Harvard Medical School, US) to discuss the latest findings from the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure trial (ARISE-HF, Applied Therapeutics, Inc) (NCT04083339).This phase 3 multicenter, randomized,… View more

Heart Failure

Prevention & Chronic Conditions
Klaus Witte
Klaus Witte is a Cardiologist at the Leeds Institute of Cardiovascular & Metabolic Medicine, Leeds, UK, where his research group focuses on patient-orientated questions with a commitment to enhancing efficacy through the personalised application of new and existing therapies in chronic heart failure (CHF).Challenging conventional teaching around heart rate and exercise capacity in CHF, Dr Witte’s… View more
THT 2025: The SUMMIT Trial
Author(s): Barry Borlaug Added: 3 months ago
THT Conference 2025 - Outcomes assessing the effect of obesity severity on tirzepatide in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) show that patients on tirzepatide with a greater reduction in BMI and baseline waist-to-height ratio had greater improvements in exercise capacity and KCCQ quality of life scores.Dr Barry Borlaug (Mayo Clinic and Foundation,… View more

Heart Failure

Prevention & Chronic Conditions
AHA 24: The ENDEAVOR Trial
Author(s): Added: 6 months ago
AHA Conference 2024 - Primary safety and efficacy results from ENDEAVOR investigating the effect of myeloperoxidase inhibition with mitiperstat (AstraZeneca) on symptoms and exercise capacity in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF).Dr Sanjiv Shah (Bluhm Cardiovascular Institute, Chicago, US) joins us onsite at AHA Conference to discuss the… View more

Heart Failure
Iron Deficiency in LVAD Patients
Author(s): William Herrik Nielsen , Finn Gustafsson Added: 11 months ago

Heart Failure
AHA 2023 CardioNerds Conference Scholars Late-Breaking Video Collection
Author(s): Mandeep Mehra , Christian Inchaustegui Added: 1 year ago
In 2023, we are excited to partner with @CardioNerds, a dynamic team dedicated to democratizing cardiovascular education. Experience a fresh perspective on the new data through an interview series featuring principal investigators and ambassadors from the CardioNerds family.These interviews are supported by an educational grant from Novo Nordisk Inc. This content is not intended for UK HCPs. View more

Heart Failure

Intervention
Frailty in Heart Failure: Insights, Patient Outcomes & Future Directions
Author(s): Karol Mirkowski , Ercole Vellone , Bernadetta Żółkowska , et al Added: 3 months ago

Heart Failure